Sanofi (SNY) Non Operating Income (2009 - 2026)
Sanofi (SNY) posted Non Operating Income of -$430.8 million for Q4 2016, down 231.0% sequentially from -$130.2 million in Q1 2016, and down 3.16% YoY from -$444.9 million in Q1 2016.
Sanofi (SNY) Non Operating Income (2009 - 2026) Analysis & Trends
Sanofi (SNY) has 8 years of Non Operating Income data on file, last reported at -$430.8 million in Q4 2016.
- Quarterly Non Operating Income fell 3.16% year-over-year to -$430.8 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$1.1 billion (down 42.67% YoY) and the FY2015 annual result came in at -$433.2 million, up 27.09% from the prior year.
- Non Operating Income declined to -$430.8 million in Q4 2016 per SNY's latest filing, from -$130.2 million in the prior quarter.
- The five-year high for Non Operating Income was -$104.1 million in Q1 2014, with the low at -$530.0 million in Q3 2013.
- Average Non Operating Income over 5 years is -$224.3 million, with a median of -$181.7 million recorded in 2013.
- Year-over-year, Non Operating Income slumped 213.93% in 2013 and soared 65.19% in 2014.
- Sanofi's Non Operating Income stood at -$256.8 million in 2012, then sank by 46.82% to -$377.0 million in 2013, then surged by 54.25% to -$172.5 million in 2014, then sank by 142.13% to -$417.6 million in 2015, then fell by 3.16% to -$430.8 million in 2016.
- Business Quant data shows SNY's Non Operating Income at -$430.8 million in Q4 2016, -$130.2 million in Q1 2016, and -$417.6 million in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -65.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -294.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -2.31 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -3.49 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | 1.23 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.23 Bn |
| Dec 31, 2025 | 9.42 Bn |
| Mar 31, 2025 | 1.08 Bn |
| Dec 31, 2024 | 6.36 Bn |
| Mar 31, 2024 | -471.48 Mn |
| Dec 31, 2023 | 7.97 Bn |
| Mar 31, 2023 | 1.65 Bn |
| Dec 31, 2022 | 8.65 Bn |
| Mar 31, 2022 | 1.92 Bn |
| Dec 31, 2021 | 9.26 Bn |
| Jun 30, 2021 | 1.72 Bn |
| Mar 31, 2021 | 2.32 Bn |
| Dec 31, 2020 | 8.32 Bn |
| Jun 30, 2020 | 2.21 Bn |
| Mar 31, 2020 | 1.72 Bn |
| Dec 31, 2019 | 6.66 Bn |
| Mar 31, 2019 | 932.04 Mn |
| Dec 31, 2018 | 4.63 Bn |
| Dec 31, 2017 | 8.01 Bn |
| Dec 31, 2016 | 8.06 Bn |